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Abstract 
Purpose of Review 
The management of patients with acute stroke has been revolutionized in recent 
years with the advent of new effective treatments.  In this rapidly evolving field, we 
provide an update on the management of acute stroke excluding thrombectomy, 
looking to recent, ongoing and future trials.  
Recent Findings 
Large definitive trials have provided insight into acute stroke care including 
broadening the therapeutic window for thrombolysis, alternatives to standard dose 
alteplase, the use of dual antiplatelet therapy early after minor ischemic stroke, and 
treating elevated blood pressure in intracerebral hemorrhage.  Further ongoing and 
future trials are eagerly awaited in this ever-expanding area. 
Summary 
Although definitive trials have led to improvements in acute stroke care, there 
remains a need for further research to improve our understanding of 
pathophysiological mechanisms underlying different stroke types with the potential 
for treatments to be tailored to the individual. 
(143/150 words) 
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Introduction 
Stroke is a common and devastating condition with a global incidence of 15 million 
people per year.1 Although one of the most exciting developments in acute ischemic 
stroke (AIS) in recent years is the proven effectiveness of thrombectomy in large 
vessel occlusion, for the remaining 85% of acute stroke patients not eligible for 
thrombectomy there have been several important developments. Here we provide an 
evidence-based update of treatments of acute stroke outwith thrombectomy, using 
data from recently published trials, and look to ongoing and future research for 
improvements in acute stroke care.  
 
Broadening the therapeutic window for use of intravenous thrombolysis in 
acute ischemic stroke patients with an unknown time of onset 
Reperfusion therapy with the intravenous (iv) thrombolytic agent, recombinant tissue 
plasminogen activator (rtPA, or alteplase), is the standard, regulatory approved, 
medical treatment for patients with AIS who present within 4.5 hours from symptom 
onset.2-4  The safety and efficacy of this treatment is now well supported by combined 
data from multiple randomized controlled trials, and confirmed by clinical registry 
experience in real life settings.5  More recently, mechanical thrombectomy has been 
shown to be effective in patients meeting certain clinical characteristics and up to 24 
hours from being last known to be well.6  
However, making treatment decisions has been particularly challenging in the nearly 
1 in 4 AIS patients who present with an unknown time of symptom onset.7  Several 
brain imaging modalities can help recognize potentially viable cerebral ischemia in 
those who present after awakening or without any history of ictus, indicating that they 
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may be candidates for iv thrombolysis with an acceptable risk.8  These include (i) 
computed tomography (CT) perfusion, (ii) mismatch between magnetic resonance 
imaging (MRI) using perfusion- weighted imaging (PWI) and diffusion- weighted 
imaging (DWI), or (iii) the visual or semi-quantitative fluid-attenuated inversion 
recovery (FLAIR)-DWI mismatch on MRI.  In the case of CT perfusion, diverse 
hemodynamic parameters, such as cerebral blood volume (CBV), cerebral blood flow 
(CBF), delay time (Tmax), and mean transit time (MTT), have been proposed as 
identifying areas of critical hypoperfusion, while the ischemic core can be defined as 
a region with markedly reduced CBV or CBF in combination with prolonged MTT or 
Tmax.  However, there is no definitive consensus on which parameters and 
thresholds best represent critical hypoperfusion and ischemic core.9-11 While PWI-
DWI mismatch is the most valid method of measuring ‘tissue at risk’, the clear 
disadvantage is the longer imaging time requirement and limited availability of MRI 
compared to CT.  In addition, there are similar difficulties with CT in determining the 
optimal thresholds for differentiating ischemic core from salvageable brain tissue.12 
New software that provide automatic quantification of ischemic core and penumbra - 
both with CT or MRI - have been developed to help physicians in clinical decision-
making with faster and easier interpretation of results, and were used in recent trials 
to broaden thrombectomy time window.13 Finally, the presence of a visible ischemic 
lesion on DWI on MRI, combined with the absence of a clearly visible hyperintense 
signal in the same region on FLAIR - the DWI/FLAIR mismatch - shows sensitivity of 
62%, specificity of 78%, and positive likelihood ratio of 3.6, for detection of 
thrombolysis-eligible AIS patients within 4.5 h of stroke onset.8 This DWI/FLAIR 
mismatch is promising in centers with MRI availability with no need of quantification, 
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to detect patients with unknown time of stroke onset who could derive benefit from iv 
thrombolysis.  
The WAKE-UP trial (The Efficacy and Safety of MRI-Based Thrombolysis in Wake-
Up Stroke) aimed to determine whether alteplase would improve functional outcome 
in AIS patients with an unknown time of stroke onset, using DWI / FLAIR mismatch 
on MRI as an eligibility criteria.14  Although the trial was stopped prematurely after 
503 patients were enrolled on anticipation of cessation of funding from the European 
Union, the study showed a significantly more favorable functional outcome at 90 days 
in those who received iv alteplase compared to those who received placebo.  Of 
note, most participants had mild baseline neurological severity (median [IQR] 
National Institute of Health stroke scale [NIHSS] score 6 [4–9]), over two thirds had 
no large vessel occlusion, and those eligible for thrombectomy were excluded.  In 
regards to safety outcomes, there were numerically more deaths and significantly 
more patients with type 2 parenchymal hemorrhage in the alteplase than placebo 
group.  In summary, this trial supports the benefit of thrombolysis reperfusion 
treatment in patients with minor or moderate AIS who have previously been denied 
such treatment.  Nevertheless, it may be that the higher serious adverse events seen 
in the alteplase group would have become significant in a larger trial.  
Alternatives to standard dose intravenous alteplase thrombolysis  
Standard recommended iv dose for alteplase in AIS is 0.9 mg/kg, with an initial 10% 
of dose given as bolus over 1 minute followed by the remainder to a maximum of 90 
mg over 60 minutes.5  Lower doses of iv alteplase (most typically, 0.6 mg/kg) have 
been used as an alternative to the standard regimen primarily on the basis of a 
perceived higher risk of intracranial hemorrhage (but also treatment affordability) in 
6 
 
Asia.15  The Enhanced Control of Hypertension and Thrombolysis Stroke Study 
(ENCHANTED) was undertaken to directly compare low-dose with standard-dose iv 
alteplase but failed to clearly show non-inferiority in the primary outcome of death or 
disability, defined by scores of 2 to 6 on the modified Rankin scale (mRS).16  
Conversely, major symptomatic intracerebral hemorrhage (sICH) was halved, and 
mortality at 7 days was also lower in the low-dose group.16  A post hoc analysis 
suggested that patients receiving either aspirin or another antiplatelet agent prior to 
thrombolysis might derive benefit from the lower dose; however, no new 
recommendations over alteplase dose have been made in recent guidelines.17  
Results from the more intensive blood pressure (BP) lowering arm of ENCHANTED 
are awaited, as they may provide new evidence to enhance the efficacy and safety of 
alteplase in AIS.  
Alternatives to alteplase in AIS have been tested although neither streptokinase 
within 6 hours nor desmoteplase within 3 to 9 hours after symptom onset showed 
benefit in randomized placebo controlled trials.18-20  Tenecteplase (TNK) is the most 
promising alternative as it has the convenience of being administered as a single iv 
bolus and shows comparable efficacy and safety to iv alteplase.21  On the basis of a 
small number of carefully selected AIS patients with CT perfusion-identified cerebral 
ischemia, TNK was shown to have significantly better reperfusion and clinical 
outcomes than alteplase,22 while the much larger Norwegian phase III trial did not 
show that TNK was clearly superior (or a priori statistically non-inferior) to alteplase in 
1,100 AIS subjects with predominantly mild deficits.23  Most recently, the EXTEND-IA 
TNK trial randomly assigned AIS patients with an occlusion of the internal carotid, 
basilar, or middle cerebral artery and who were eligible for thrombectomy to receive 
TNK (at a dose of 0.25 mg per kilogram of body weight; maximum 25 mg) or 
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standard dose alteplase within 4.5 hours after symptom onset.24  Reperfusion of 
greater than 50% of the involved ischemic territory or an absence of retrievable 
thrombus at the time of the initial angiographic assessment were more than double in 
patients treated with TNK compared to alteplase.  Moreover, TNK resulted in a better 
90-day functional outcome than alteplase, and without any difference in sICH 
between the groups. TNK is not yet an approved treatment for AIS and results of 
ongoing trials are awaited.  
Another emerging AIS treatment strategy is use of an iv antiplatelet agent.  A 
Cochrane review of iv glycoprotein IIb/IIIa receptor antagonists for AIS found these 
agents to be associated with a significant risk of ICH without any measurable 
improvement in death or disability.25  However, a majority of the trial data involved 
the use of abciximab.26  Regarding other IV glycoprotein IIb/IIIa receptor antagonists, 
single-arm and phase II studies of eptifibatide as adjunctive therapy to iv alteplase 
support ongoing trials to establish safety and efficacy,27, 28 where the rate of sICH 
does not appear to be increased when used in in combination with standard dose 
alteplase.28  Results demonstrating comparable safety of this new regime with 
historical rates of sICH with tPA alone may prompt new trials evaluating alteplase 
combined with eptifibatide to improve outcomes after AIS.   
Improving stroke systems of care 
Well organized stroke care has demonstrated improved patient outcomes.29, 30  
Having organized local stroke care protocols, established goals and quality 
improvement strategies, all have an important role in stroke care.31  Unfortunately, 
considerable regional differences remain in optimal stroke care, including access to 
stroke units,32 particularly in low resource settings.  Such disparities require further 
urgent attention to reduce the burden of stroke, in particular in low and middle-
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income countries where fewer resources are available and stroke rates are 
increasing. 
Key elements for effective stroke treatment are: (a) early symptom recognition and 
prompt health system access; and (b) organized system response, triage and 
management, once stroke is detected.  In less resourced areas, early recognition, 
rapid transport and ready access to thrombolysis are major barriers, whereas in more 
mature systems, attention has shifted to bypass algorithms to offer patients the most 
appropriate and efficient treatment approach, reduce treatment times, and extend 
stroke care to facilities to where thrombolysis has been absent. 
A regional system of stroke care, with operationalized bypass algorithms according to 
local resources, is a critical aspect comprising healthcare facilities where initial 
emergency care, including administration of iv alteplase can be provided; and centers 
capable of performing endovascular stroke treatment with comprehensive 
periprocedural care to which rapid transport can be arranged.  Patients with a 
positive stroke screen (i.e. the face, arm, speech, time [FAST] algorithm) and/or a 
strong suspicion of stroke should be transported rapidly to the closest healthcare 
facility available for administration of iv alteplase, since recovery is strongly 
dependent on the time to treatment.33  When several iv alteplase–capable hospital 
options exist within a defined geographic region, the benefit of bypassing the closest 
to bring the patient to one that offers a higher level of stroke care is still uncertain.  A 
number of stroke severity scales targeted at recognition of large vessel occlusion 
(LVO) in the prehospital setting are available, but their prediction is uncertain for 
recommending wider use for direct patient transfer to thrombectomy-capable 
centers.34 
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Door-to-needle time (DNT) is a key performance indicator for efficient use of iv 
thrombolysis in AIS.  Thus, quality improvement strategies have been developed to 
reduce treatment delays to thrombolysis.35  One of them, the Helsinki stroke model, 
consists of 12 interventions involving patient pre-notification, rapid clinical 
assessment, image acquisition, and treatment administration in a chain of responses 
requiring parallel processing by on-site radiology and stroke/neurology personnel.36  
When applied in hospitals lacking a dedicated neurological emergency department or 
electronic patient records, it has led to an 18-minute reduction in in-hours DNT.37  A 
key success factor is the close cooperation of ambulance, emergency, and stroke 
teams.  The transferability and impact on DNT of the Helsinki stroke thrombolysis 
model has been tested in hospitals with ‘real-word’ resources, showing a striking 
reduction in median in-hours DNT from 87 to 34 min.38  
Another barrier to appropriate stroke treatment is the lack of specialized stroke care 
in the emergency department, which can be critical in less resourced areas.  The use 
of telemedicine (or telestroke) seeks to overcome this gap by providing centralized 
stroke care to a network of emergency departments through video consultation and 
examination of patients.39  Telestroke iv thrombolysis for patients with AIS has been 
shown to be safe and effective within a 3-hour time window, with similar rates of sICH 
and no difference in mortality or functional independence at 3 months when 
compared to iv alteplase provided at established stroke centers.40  As shown in other 
health problems, it is expected that the use of new technologies, such as 
telemedicine, will provide greater reach and improved stroke treatment in an 
economical manner.   
Antiplatelets 
The risk of recurrent vascular events after an AIS or transient ischaemic attack (TIA) 
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is highest soon after the event and declines over subsequent weeks.41  Although 
aspirin has been shown to clearly reduce the risk of early and long-term 
recurrence,42, 43 there has been interest in examining the efficacy and safety of short-
term use of dual antiplatelet therapy with aspirin and clopidogrel following minor 
stroke or high-risk TIA.  The Chinese Clopidogrel in High-Risk Patients with Acute 
Nondisabling Cerebrovascular Events (CHANCE) trial found that combined aspirin 
and clopidogrel, commenced within 24 hours of onset and continued for 21 days, was 
superior to aspirin alone in preventing recurrent vascular events within 90 days in 
5170 patients with minor AIS or TIA, with no apparent increase in hemorrhagic 
complications.44, 45  Recently, the US-initiated Platelet-Oriented Inhibition in New TIA 
and minor ischaemic stroke (POINT) trial, assessed the combination of aspirin and 
clopidogrel versus aspirin alone for 90 days in 4881 patients within 12 hours of minor 
stroke or TIA.  Dual antiplatelet therapy was associated with a lower risk of major 
ischemic events but a higher risk of major hemorrhage at 90 days and, on the advice 
of the trial’s data safety monitoring committee, was stopped early.46  
A newer antiplatelet agent, ticagrelor, licensed for use in coronary artery disease, has 
also been assessed against aspirin within 24 hours of minor AIS or TIA in over 
13,000 patients.47  Compared with aspirin, ticagrelor was not superior at reducing the 
rate of combined or individual components of the endpoint of stroke, myocardial 
infarction or death at 90 days and was not approved for secondary stroke prevention.  
However, in a pre-specified exploratory analysis involving 3081 participants with 
ipsilateral atherosclerotic stenosis, ticagrelor was superior to aspirin at preventing the 
primary vascular outcome.48  
As it appears that short-term dual antiplatelet therapy offers some superiority over 
monotherapy, a question existed as to whether triple therapy would be even better?  
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The Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) 
trial assessed the combination of aspirin, clopidogrel and dipyridamole compared 
with guideline-recommended therapy (clopidogrel or combination aspirin and 
dipyridamole) commenced within 48 hours of the onset of AIS or TIA in 3096 
patients.49  Triple therapy did not reduce stroke recurrence but did cause more, and 
more severe, bleeding than guideline antiplatelet therapy.  In contrast to the previous 
trials, TARDIS included patients up to 48 hours after symptom onset and with more 
severe stroke, in whom 11% were thrombolysed.  
In summary, recent trials highlight that early treatment with dual antiplatelet therapy 
in minor AIS or TIA is beneficial, whilst later intensive treatment increases bleeding 
without any additional benefits derived from reducing recurrent serious vascular 
events.  The optimum treatment duration with dual antiplatelet therapy is unclear and 
further analyses to assess whether efficacy can be achieved without compromising 
safety are needed. Furthermore, a better understanding of underlying stroke 
mechanisms and etiologies may assist future research in refining approaches 
towards safe and efficacious treatments.  
Physiological management 
Head positioning  
A survey of clinical practice shows considerable variation in the use of head 
positioning to benefit patients with acute stroke across different health care 
settings.50  In part, this relates to the variable uptake and residual uncertainty over 
the evidence indicating that the lying flat head position may benefit AIS patients from 
enhancing cerebral blood flow.51-53  However, a large pragmatic study that used an 
innovative cluster crossover design to apply lying flat versus elevated head 
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positioning as a standard of care failed to show any difference in 90-day functional 
outcomes between the randomized groups.53-55   
Control of elevated blood pressure (BP) 
High BP is present in the majority of patients with acute stroke56 and predicts 
increased risks of recurrent AIS,57 hematoma expansion in acute ICH,58 and death 
and dependency in both stroke types.59, 60  Whether or not lowering elevated BP in 
acute stroke provides any benefit over the plausible risks of cerebral ischemia has 
been hotly debated, and despite several large trials being conducted, the evidence 
remains uncertain albeit with less margin.61  
Two trials have focussed on acute ICH – the main Intensive blood pressure reduction 
in acute cerebral hemorrhage trial (INTERACT2, n=2794)62 and the main 
Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-II, n=1000)63 – 
and have led to changes in clinical practice.  In the former, intensive BP lowering 
(systolic target <140 mmHg) within 6 hours of symptom onset in INTERACT2 was 
associated with a positive shift in favorable functional outcome and improved quality 
of life but was neutral on primary dichotomized analysis of the mRS, compared to 
conventional recommended BP lowering (systolic target <180 mmHg).  Conversely, 
the latter trial showed that more intensive (achieved systolic 110-139 mmHg) versus 
‘standard’ (range 140-179 mmHg, most around 140 mmHg) BP lowering using 
predominantly a single agent, nicardipine, within 4.5 hours of stroke onset was 
neutral.  Following publication of INTERACT-2, many guidelines were updated in 
recommending early and intensive BP lowering to a systolic 140mmHg64-66 but 
publication of ATACH-II has caused some guidelines to caution intensive BP 
lowering in ICH.67, 68  However, it is important to note that INTERACT-2 and ATACH-
II have crucial differences in the way in which BP was managed.  Firstly, the BP 
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lowering effect of nicardipine in attenuating hematoma growth (and clinical outcome) 
may have been negated by its mild antiplatelet action. Second, systolic BP eligibility 
for inclusion differed between the trials (INTERACT2: 150-220 mmHg; ATACH-II 
≥180 mmHg) with many ATACH-II participants receiving BP lowering prior to 
randomization.  Third, the more aggressive approach to BP lowering in both arms of 
ATACH-II resulted in the guideline group having a similar on-treatment BP profile to 
the intensive group in INTERACT2.  As such, a lower systolic target of 110-139 
mmHg maybe too low and aggressive than the <140mmHg within 1 hour used in 
INTERACT2.61  
Current guidelines recommend lowering elevated BP to <185/110 mmHg in the 
setting of thrombolysis for AIS.66-68  The results of the ENCHANTED-BP trial, which is 
assessing whether more intensive BP lowering (systolic <140 mmHg) improves 
outcome in patients undergoing thrombolysis are awaited in 2019.69  Several large 
trials have assessed BP lowering in AIS and found it to be safe and feasible but 
without influencing overall clinical outcome.70  Early treatment (<6 hours) with 
transdermal glyceryl trinitrate (GTN) was associated with improved clinical outcomes 
in a subgroup of the Efficacy of Nitric Oxide in Stroke (ENOS) trial,71 in line with a 
small, single-center, ambulance-based study assessing the same medication.72  The 
larger (n~1000) Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke 
Trial-2 (RIGHT-2) is assessing transdermal GTN within 4 hours of symptom onset in 
a relatively unselected pre-hospital stroke population.73 
Oxygen 
Hypoxia is common, affecting two thirds of people with acute hemiparetic stroke,74 
and most often intermittent and undetected, yet associated with higher rates of poor 
outcomes including neurological deterioration,75 death, and death and 
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institutionalisation.76  The Stroke Oxygen Study (SOS) trial assessed the 
effectiveness of prophylactic low-dose oxygen therapy for three days in 8003 non-
hypoxic individuals with acute stroke and found no difference in 90 day death or 
disability between treatment groups.77  However, participants mainly had mild strokes 
(NIHSS score median 5) and were recruited an average of 20 hours after symptom 
onset.  Thus, whether oxygen therapy is beneficial in the first few hours of acute 
stroke remains unclear.  High-flow oxygen therapy is currently being tested in AIS 
patients with the rationale that oxygenation of ischemic and surrounding tissues may 
be protective in those patients with more severe strokes mediated by large vessel 
occlusion.78  In the meantime, oxygen supplementation should be limited to those 
with reduced saturations (<95%) and without any contraindications.66 
Glucose 
High glucose within the first 24 hours of onset has been associated with poor 
outcome following both AIS and acute ICH.  However, glycemic control has not been 
shown to improve outcome after AIS.79  Therefore, guidelines recommend a medium 
level range of target blood glucose levels in AIS: 7.8-10 mmol/L17 versus. 5-15 
mmol/L.66  The third in the series, INTERACT-3, is currently assessing more early 
and intensive glucose management as part of a bundle of care, for improving 
outcome in acute ICH (NCT03209258). 
Oedema 
In the setting of malignant middle cerebral artery infarction with associated cerebral 
edema, decompressive hemicraniectomy is a proven life-saving treatment in those 
aged >60 years – with a similar survival benefit to younger patients – within 48 hours 
of symptom onset.17, 66  Therefore, prompt referral for neurosurgery in suspected 
cases is required for a shared decision-making approach to ensure agreement over 
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the potential for surviving with residual disability.  Medical therapies for cerebral 
oedema are commonly used in clinical practice, but have limited proven benefit.  
Mannitol, an intravascular osmotic agent, reduces cerebral oedema and lowers 
intracranial pressure but there is no trial evidence of efficacy in either AIS or ICH.80  
In INTERACT-2, mannitol use was common (two thirds) but safe and without any 
influence on outcome in a post-hoc analysis.81  The sulfonylurea receptor 1 inhibitor 
glibenclamide given initiated within 10 hours and continued for 3 days after large 
anterior circulation AIS has been shown to improve markers of cerebral oedema, but 
not surprisingly, no effect on clinical outcome was shown in a small (n=86) phase II 
trial.82  Future trials of medical therapies in cerebral oedema in both AIS and ICH are 
needed. 
Treatment failures 
Neuroprotection 
Despite numerous trials of pharmacological and non-pharmacological therapies with 
putative neuroprotective mechanisms, none have proved efficacious in acute stroke, 
and are therefore not recommended.17 Whether neuroprotective therapies have a 
role in patients  eligible for recanalization in AIS is unclear, and requires further 
study. 
Early anticoagulation 
A Cochrane review found that early anticoagulation within 14 days of AIS was not 
associated with any net short- or long-term benefit in 24 trials totalling 23,748 
patients.83  Anticoagulation increased bleeding risk despite reducing rates of stroke 
recurrence, deep vein thrombosis and pulmonary embolus.  Thus, the benefits of 
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anticoagulation are offset by increased bleeding and are not recommended routinely 
early after AIS.17  
 
Conclusion 
In summary, there have been significant improvements in our understanding of, and 
potential ability to treat, acute stroke. Recent large trial results need to be adopted by 
national and international guidelines to aid implementation into clinical practice. 
There remains a need for further research to improve our understanding of the 
pathophysiological mechanisms underlying different stroke types so that, in future, 
treatments can be tailored to the individual stroke patient. 
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Table 1: Summary of recent major acute stroke trial results  
 Trial Population Intervention Outcome Comment 
Thrombolysis for AIS      
Broadening the 
thrombolysis time window 
WAKE-UP 503 AIS patients with 
unknown time of 
onset 
MRI DWI/FLAIR 
mismatch: alteplase vs. 
placebo 
More favorable functional 
outcome at 90 days in 
alteplase vs. placebo groups 
Alteplase is safe and 
efficacious when using MRI 
DWI/FLAIR mismatch 
eligibility 
Lower dose alteplase (0.6 
mg/kg) 
ENCHANTED 3310 AIS patients 
within 4.5 hours of 
onset 
Alteplase 0.6 mg/kg vs. 
0.9 mg/kg 
Failed to show non-inferiority Post-hoc analysis: those 
on antiplatelet agents may 
benefit from lower dose 
Tenecteplase (TNK) NOR-TEST 1100 AIS patients 
within 4.5 hours of 
onset 
TNK 0.4 mg/kg vs. 
alteplase 0.9 mg/kg 
No difference in functional 
independence by day 90 
Predominantly mild strokes 
and a high proportion of 
mimics recruited 
 EXTEND-IA 202 AIS within 4.5hrs 
with large vessel 
occlusion eligible for 
thrombectomy 
TNK 0.25 mg/kg vs. 
alteplase pre-
thrombectomy 
TNK resulted in increased 
recanalization rates at 
angiography and improved 
90 day functional outcome 
No difference in 
symptomatic ICH rates 
Antiplatelets      
Dual antiplatelet therapy 
(DAPT) in minor stroke 
and TIA 
CHANCE 5170 minor stroke or 
TIA patients within 
24 hours of onset 
Clopidogrel + Aspirin vs. 
aspirin alone for 21 days 
DAPT reduced recurrent 
vascular events without 
increasing hemorrhage rates 
at 90 days 
Chinese population 
 POINT 4881 minor stroke or 
TIA patients within 
12 hours of onset 
Clopidogrel + Aspirin vs. 
aspirin alone for 90 days 
DAPT reduced major 
ischemic events but 
increased major hemorrhage 
rates at 90 days 
Trial stopped early 
Ticagrelor SOCRATES 13000 minor stroke 
or TIA within 24 
hours of onset 
Ticagrelor vs. Aspirin Ticagrelor not superior to 
aspirin 
In a secondary analysis, 
Ticagrelor was superior to 
aspirin in those with 
ipsilateral carotid stenosis 
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Triple antiplatelets in 
stroke and TIA 
TARDIS 3096 stroke or TIA 
patients within 48 
hours of onset 
Aspirin + Dipyridamole + 
Clopidogrel vs. guideline 
therapy (Aspirin + 
Dipyridamole or 
Clopidogrel only) for 28 
days 
Triple therapy did not reduce 
stroke recurrence but did 
increase bleeding 
Trial stopped early due to 
futility 
11% thrombolysed 
Head positioning HEADPOST 11093 acute stroke 
patients 
Lying flat vs. elevated 
head positioning for 24 
hours 
No difference in 90-day 
functional outcome 
Mild strokes 
Position initiated an 
average of 14 hours after 
symptom onset 
Control of elevated BP INTERACT2 2794 ICH patients 
within 6 hours of 
onset 
Intensive (systolic target 
<140 mmHg) vs. 
guideline (<180 mmHg) 
Intensive: favorable shift in 
functional outcome, improved 
quality of life 
Mixture of agents used 
 ATACH-II 1000 ICH patients 
within 4.5 hours of 
onset 
Intensive (110-139 
mmHg) vs. ‘standard’ 
(140-179 mmHg) 
No difference in 90-day 
functional outcome 
Predominantly nicardipine  
Oxygen SOS 8003 non-hypoxic 
acute stroke patients 
Prophylactic low-dose 
oxygen therapy vs. none 
for 3 days 
No difference in 90-day 
functional outcome 
Mild strokes, recruited an 
average of 20 hours after 
symptom onset 
 
